By Katherine Cheung, David B. Yaden, and Brian D. Earp Classic psychedelics, such as psilocybin and LSD, are currently being studied for their potential therapeutic impact — primarily in conjunction with some form of psychotherapy — on a variety of conditions. Within such a clinical frame, the potential value of psychedelic-assisted therapy is largely assumed… Read More »Are psychedelic Experiences Intrinsically Valuable?
Written by Doug McConnell
Boris Johnson, Rishi Sunak, and Liz Truss are on psychedelics at the Palace of Westminster. This isn’t the work of Russian spies who have dusted off the KGB playbook or yet another Downing Street party but, rather, a near-future professional development program for politicians.
The path to this near-future scenario has two steps. First, let us suppose that psychedelics make good on their early promise as moral bioenhancers. Second, once effective moral enhancements exist, then people whose jobs entail making morally momentous decisions, such as politicians, would be morally required to take those enhancements.Read More »Parliament Psychedelic
